Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.
Dixon-Zegeye M, Shaw R, Collins L, Perez-Smith K, Ooms A, Qiao M, Pantziarka P, Izatt L, Tischkowitz M, Harrison RE, George A, Woodward ER, Lord S, Hawkes L, Evans DG, Franklin J, Hanson H, Blagden SP. Dixon-Zegeye M, et al. Among authors: blagden sp. Trials. 2024 Feb 3;25(1):103. doi: 10.1186/s13063-024-07929-w. Trials. 2024. PMID: 38308321 Free PMC article.
Drugging cell cycle kinases in cancer therapy.
Blagden S, de Bono J. Blagden S, et al. Curr Drug Targets. 2005 May;6(3):325-35. doi: 10.2174/1389450053765824. Curr Drug Targets. 2005. PMID: 15857291 Review.
Docetaxel in the management of ovarian cancer.
Blagden SP, Kaye SB. Blagden SP, et al. Expert Rev Anticancer Ther. 2005 Apr;5(2):203-14. doi: 10.1586/14737140.5.2.203. Expert Rev Anticancer Ther. 2005. PMID: 15877518 Review.
Making sense of antisense.
Vidal L, Blagden S, Attard G, de Bono J. Vidal L, et al. Eur J Cancer. 2005 Dec;41(18):2812-8. doi: 10.1016/j.ejca.2005.06.029. Epub 2005 Nov 9. Eur J Cancer. 2005. PMID: 16289851 Review.
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours.
Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, De-Bono JS, Steward W. Greystoke A, et al. Ann Oncol. 2006 Aug;17(8):1313-9. doi: 10.1093/annonc/mdl097. Epub 2006 May 25. Ann Oncol. 2006. PMID: 16728482 Free article. Clinical Trial.
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.
Scott EN, Thomas AL, Molife LR, Ahmed S, Blagden S, Fong PC, Kowal K, McCoy C, Wiesinger H, Steward W, De Bono J. Scott EN, et al. Cancer Chemother Pharmacol. 2009 Jul;64(2):425-9. doi: 10.1007/s00280-009-0968-y. Epub 2009 Mar 12. Cancer Chemother Pharmacol. 2009. PMID: 19280191 Free article. Clinical Trial.
91 results